Back to top
more

Emergent Biosolutions (EBS)

(Delayed Data from NYSE)

$9.35 USD

9.35
1,634,358

+0.41 (4.59%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $9.23 -0.12 (-1.28%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Should You Invest in the Invesco SP SmallCap Health Care ETF (PSCH)?

by Zacks Equity Research

Sector ETF report for PSCH

Axsome Focuses on Filling NDAs for Two CNS Candidates in 2020

by Zacks Equity Research

Axsome's (AXSM) CNS pipeline candidates are advancing well. NDAs for AXS-05 to address MDD and AXS-07 as an acute treatment of migraine will be filed in Q4. Lack of a marketed product is a concern.

Ceylad Gets FDA Nod to Begin Phase I Study on CAR T Candidate

by Zacks Equity Research

Celyad (CYAD) gets the FDA's permission to begin a phase I study on its lead CAR T candidate, CYAD-211, for the treatment of relapsed/refractory multiple myeloma.

Zacks.com featured highlights include: Nautilus, Ameresco, Canadian Solar, Emergent BioSolutions and Pacira BioSciences

by Zacks Equity Research

Zacks.com featured highlights include: Nautilus, Ameresco, Canadian Solar, Emergent BioSolutions and Pacira BioSciences

Blueprint Medicines, Roche to Develop Pralsetinib for Cancer

by Zacks Equity Research

Blueprint Medicines (BPMC) signs a contract with Roche to commercialize pralsetinib for treating patients with RET-fusion NSCLC, RET-mutant MTC, other thyroid cancers and other solid tumors.

Axsome's NDA for Depressive Disorder Drug on Track in Q420

by Zacks Equity Research

Axsome (AXSM) concludes a favorable pre-NDA meeting with the FDA officials for AXS-05 to treat major depressive disorder. The company is on course to file the NDA in Q4.

FDA Grants Extra Access to Vanda's Tradipitant to a Patient

by Zacks Equity Research

Vanda (VNDA) gets authorization from the FDA for expanded access to tradipitant for a single patient for six more months.

Nalak Das headshot

5 Stocks With Recent Price Strength Despite Market Volatility

by Nalak Das

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

Emergent Biosolutions (EBS) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Emergent Biosolutions (EBS) closed at $94.23 in the latest trading session, marking a -0.26% move from the prior day.

AbbVie (ABBV) Gets FDA Nod for Another Botox Label Expansion

by Zacks Equity Research

AbbVie (ABBV) wins the FDA nod for an expanded use of Botox to treat spasticity in pediatric patients aged two years and above including those with lower limb spasticity caused by cerebral palsy.

Is Emergent Biosolutions (EBS) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (EBS) Outperforming Other Medical Stocks This Year?

Emergent (EBS) Stock Up Year to Date on Coronavirus Vaccine Deals

by Zacks Equity Research

Emergent (EBS) inks deals with multiple companies to provide manufacturing services for helping them develop COVID-19 vaccine.

Abeona Restarts Enrollment in Connective Tissue Disorder Study

by Zacks Equity Research

Abeona (ABEO) restarts patient enrollment in phase III VIITAL study of EB-101 for the treatment of recessive dystrophic epidermolysis bullosa.

Sreoshi Bera headshot

6 Stocks to Wade Through the Spike in Coronavirus Cases

by Sreoshi Bera

The current health scare drives market volatility and calls for investment in consumer staples, healthcare and IT sectors for stable returns.

Emergent's (EBS) 5-Year Deal to Back J&J's Coronavirus Vaccine

by Zacks Equity Research

Emergent BioSolutions (EBS) extends a five-year deal with J&J to provide its CDMO services to produce the drug substance of the latter's COVID-19 vaccine candidate. Shares rise.

Will Emergent BioSolutions' Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Emergent BioSolutions

AbbVie (ABBV) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

AbbVie (ABBV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Blueprint Medicines Files NDA to FDA for Pralsetinib in MTC

by Zacks Equity Research

Blueprint Medicines (BPMC) files an NDA to the FDA for pralsetinib to treat patients with advanced/metastatic RET mutant medullary thyroid cancer and RET fusion-positive thyroid cancers. Stock up.

Amgen (AMGN) Looks Good: Stock Adds 8.2% in Session

by Zacks Equity Research

Amgen (AMGN) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Ultragenyx (RARE) Looks Good: Stock Adds 8.2% in Session

by Zacks Equity Research

Ultragenyx (RARE) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Ultragenyx's Dojolvi Gets FDA Nod to Treat Rare Disease

by Zacks Equity Research

Ultragenyx (RARE) gets FDA approval forDojolvi for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders.

Akero Therapeutics (AKRO) Jumps: Stock Rises 8.9%

by Zacks Equity Research

Akero Therapeutics (AKRO) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Eidos Therapeutics (EIDX) Looks Good: Stock Adds 6.4% in Session

by Zacks Equity Research

Eidos Therapeutics (EIDX) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

3 Reasons Why Emergent Biosolutions (EBS) Is a Great Growth Stock

by Zacks Equity Research

Emergent Biosolutions (EBS) could produce exceptional returns because of its solid growth attributes.

Ascendis Submits BLA to FDA for TransConhGH in Pediatric GHD

by Zacks Equity Research

Ascendis Pharma (ASND) submits BLA to the FDA for TransConhGH for the treatment of pediatric growth hormone deficiency.